The center has tested 68 crores of doses for 130 crores of Serum Institute Indian citizens in June next year.
India’s first COVID vaccine, the Serum Institute’s “Covishield,” will hit the market in 73 days. Indians are vaccinated free of charge under the National Immunization Program (NIP), as is the case with all other vaccines.
“The government is permitting a ‘Priority Manufacturing License’ and speeding up the trial protocol processes so that the trial completes 58 days. The second dosing will give at 29 days. Final test data will be available within 15 days after the second test.
At this point, we plan to commercialize Covishield “, a senior official at the Serum Institute of India (SII).
Previously, attempts at the third phase had to last at least 7 to 8 months.
The trial among 1,600 volunteers at 17 centers with about 100 volunteers each began on August 22.
According to the source, the vaccine would be owned by the Serum Institute. The company would have an exclusive contract with Astra Zeneca to buy rights and pay a royalty for its private sale in India and 92 other countries.
The central government has already told the SII that it will obtain the vaccines directly and plans to vaccinate the indigenous people for free. The center has examined 68 crore doses for 130 crore Indians by the Serum Institute in June next year.
By the way, you will probably order “Covaxine,” which is under development by ICMR and Bharat Biotech, and “ZyCoV-D” from Zydus Cadila, if your trials are successful.
Bharat Biotech has not yet indicated when the trials will start and end. However, Bharat Biotech’s CMD Krishna Ella has stated that she will not use shortcuts to speed up the vaccine for safety and effectiveness.
The serum will start producing doses of 6 crores per month, increasing to 10 crores per month until April 2021. To this end, the vaccine production lines are being reorganized, for which it has spent almost 200 million rupees. IBS, the world’s largest vaccine manufacturer, can produce doses of 150 crores per year.
The Bill and Melinda Gates Foundation has agreed to fund approximately $ 150 million (nearly Rs 1.125 billion) of serum to manufacture and administer about 10 million doses of the Covid-19 vaccine to serve low-income countries. This will help IBS reduce the price from more than Rs 1,000 per treatment to around Rs 250 per dose, the source said.